Lyric Bio

Lyric Bio, Inc. is on a mission to reshape the global supply of life-saving medicines with its next-generation biomanufacturing platform. Every year, thousands of patients with immune deficiencies and neurological disorders rely on intravenous immunoglobulin (IvIg), but supply remains critically limited—often falling short of growing needs. The global IvIg market is already valued at over $20 billion and is projected to see strong growth as both diagnosis rates and clinical indications rise. Yet, traditional plasma-derived processes cannot keep pace, leaving patients and clinicians facing persistent shortages. Lyric Bio stands at the forefront of this market opportunity, unlocking scalable, efficient production technology to break through the bottlenecks that have long constrained access. For patients, Lyric Bio’s innovation means hope—offering the promise of consistent, reliable access to high-quality therapies. By reimagining how essential biologics like IvIg are made, Lyric Bio is delivering groundbreaking technology that will enable first in vitro production other donor derived complex therapeutics such as stem cells and red blood cells.